Doubts cast on the molecular mechanism of 'read-through' drug PTC124/Ataluren
A drug developed to treat genetic diseases such as Duchenne muscular dystrophy and cystic fibrosis may need a radical rethink. In a new study published on 25 June in the open access journal PLOS Biology, researchers question ...
Jun 25, 2013
0
0